Supplementary data from:

The gut microbiome in patients with Cushing's syndrome is severely altered

German Rubinstein<sup>1</sup>, Ilias Lagkouvardos<sup>2,3</sup>, Evangelia Intze<sup>2</sup>, Andrea Osswald<sup>1</sup>,

Stephanie Zopp<sup>1</sup>, Katrin Ritzel<sup>1</sup>, Leah Theresa Braun<sup>1</sup>, Adriana Albani<sup>1</sup>, Heike Künzel<sup>1</sup>,

Anna Riester<sup>1</sup>, Felix Beuschlein<sup>1,2</sup>, Martin Reincke<sup>1\$</sup>

The associated article has been submitted to Metabolism.

Please cite the original article when using these data.

Figure 1: A: Rarefaction curves of both patients' and lean controls samples. B: Beta-diversity

shown as MDS plot of the microbial profiles from the patients with active CS, CS in remission

and obese control patients. C: Calinski-Harabasz index showing the optimal number of clusters

for Partitioning Around Medoids (PAM) clustering. D: MDS plot of microbial profiles of

students from years 2016 and 2019 showing an overlap of the samples. E: Distances of the

groups to their closest medoid. The first panel presents the distances of the 2016's (as three


clusters and as a whole) and 2019's students from the closest medoid of the 2016's students.

The second panel compares the distances of the students as a whole (2016 and 2019) from

the medoids of the 2016's students and the medoids of the combined group (2016 and 2019).

Table 1: Clinical and biochemical data of patients with Cushing's syndrome according to their

microbial cluster.



x/yM: distances of the profiles in group x to the closest medoid of group y

Table 1:

	CS 2	ctivo	1
	CS active (n=18)		
	Cluster 1	Cluster 2	P-value
	CSA 1	CSA 2	CSA 1 vs.
	(n=11)	(n=7)	CSA 2
	Pituitary: 9	Pituitary: 4	
Etiology of CS	Adrenal: 2	Adrenal: 1	
	Ectopic: 0	Ectopic: 2	
Age [y]	45 ± 15	40 ± 15	0.479
Sex (F/M)	F: 6 M: 5	F: 5 M: 2	0.474
Weight [kg]	88 ± 25	76 ± 11	0.536
Height [m]	$1.76 \pm 0.1$	$1.65 \pm 0.1$	0.006
BMI [kg/m²]	28.3 ± 7.4	27.7 ± 3.8	0.724
Waist to Hip ratio	$0.93 \pm 0.1$	$0.92 \pm 0.08$	0.791
Care	l diovascular risk facto	ors	
Prediabetic state or	4/11	4/7	0.387
Diabetes mellitus			0.733
Glucose [mg/dl]	108 ± 49	103 ± 29	0.930
HbA1c [%]	$5.97 \pm 0.85$	5.9 ± 1	0.518
Hypertension	8/11	6/7	
Systolic Blood Pressure [mmHg]	131 ± 19	$158 \pm 35$	0.069
Diastolic Blood Pressure [mmHg]	86 ± 16	105 ± 19	0.069
Triglycerides [mg/dl]	88 ± 28	$104 \pm 34$	0.404
Cholesterol [mg/dl]	193 ± 43	$184 \pm 38$	0.591
LDL-Cholesterol [mg/dl]	$119 \pm 40$	$115 \pm 32$	0.733
HDL-Cholesterol [mg/dl]	60 ± 10	53 ± 15	0.350
Q	uality of Life Survey	s	
BDI I – II	17.75 ± 11.6	$11.83 \pm 7.83$	0.228
Tuebingen CD-25	$32.6 \pm 19.2$	39.2 ± 15	0.622
Cushing QoL	$48.5 \pm 25.8$	53 ± 21.8	0.573
In	fection/Inflammation	n	•
Infectious complications	0/11	1/7	0.197
(with inpatient treatment)	U/11	1//	
Infectious complications (with outpatient treatment)	3/11	2/7	0.952
Leukocytes [G/I]	8.01 ± 1.68	$8.89 \pm 2.09$	0.425
	<u> </u>		1

CRP [mg/dl]	$0.17 \pm 0.21$	$0.73 \pm 0.89$
Ві	iochemical testing of	CS
Baseline Cortisol [μg/dl]	23.5 ± 10.7	29.3 ± 16.5
Cortisol after 1mg Dexamethasone [µg/dl]	14.5 ± 11	18.3 ± 12
LSST [ng/ml]	9.2 ± 9.7	$68.7 \pm 108.5$
UFC [μg/24h]	422 ± 265	2043 ± 3883